share_log

Deciphera's Cancer Drug Tops Pfizer's Sutent On Safety Front In Gastrointestinal Cancer

Deciphera's Cancer Drug Tops Pfizer's Sutent On Safety Front In Gastrointestinal Cancer

Deciphera抗癌药物超越辉瑞在胃肠道癌症安全方面的地位
Benzinga Real-time News ·  2022/08/11 09:46
  • The Journal of Clinical Oncology has published results from Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) INTRIGUE Phase 3 study of Qinlock (ripretinib) for advanced gastrointestinal stromal tumor (GIST) previously treated with Novartis AG's (NYSE:NVS) Gleevec/Glivec (imatinib). 
  • Although Qinlock did not offer a statistically significant improvement in progression-free survival (PFS) compared to sunitinib, the drug showed meaningful clinical activity with fewer Grade 3/4 treatment-emergent adverse events and improved tolerability.
  • In addition, Qinlock had a more favorable safety profile than Pfizer Inc's (NYSE:PFE) Sutent (sunitinib), with fewer Grade 3/4 adverse events.
  • Patients in the Qinlock arm reported less deterioration in role functioning and better outcomes than sunitinib.
  • In patients with a KIT exon 11 primary mutations, ripretinib demonstrated a median PFS (mPFS) of 8.3 months compared to 7.0 months for the sunitinib arm. 
  • In the intention-to-treat (ITT) population, ripretinib demonstrated an mPFS of 8.0 months vs. 8.3 months.
  • In patients with a KIT exon 11 primary mutations, ripretinib demonstrated an objective response rate of 23.9% vs. 14.6%, and 21.7% vs. 17.6% in the ITT populations.
  • The FDA has approved Qinlock for advanced GIST patients who have received prior treatment with three or more kinase inhibitors.
  • Price Action: DCPH shares traded 3.66% lower at $16.57 on the last check Thursday.
  • 《临床肿瘤学杂志》发表了来自Deciphera制药公司纳斯达克：DCPH关于秦洛克(利普替尼)治疗晚期胃肠道间质瘤的有趣的3期研究诺华制药(纽约证券交易所代码：NVS)Gleevec/Glivec(伊马替尼)。
  • 尽管与舒尼替尼相比，秦洛克在无进展存活率(PFS)方面没有提供统计上的显著改善，但该药物显示出有意义的临床活性，3/4级治疗--紧急不良事件和耐受性得到改善。
  • 此外，秦锁的安全状况比辉瑞(纽约证券交易所股票代码：PFE)舒坦(孙尼替尼)，3/4级不良事件较少。
  • 秦锁臂的患者报告说，与舒尼替尼相比，角色功能恶化较少，结果更好。
  • 在KIT外显子11原发突变的患者中，利普替尼的中位PFS(MPFS)为8.3个月，而舒尼替尼组为7.0个月。
  • 在意向治疗(ITT)人群中，利普替尼的MPFS为8.0个月，而不是8.3个月。
  • 在KIT外显子11原发突变的患者中，利普替尼在ITT人群中的客观应答率分别为23.9%和21.7%，分别为14.6%和17.6%。
  • FDA已经批准Qinlock用于先前接受过三种或更多激酶抑制剂治疗的晚期GIST患者。
  • 价格行动：在周四的最后一次检查中，DCPH的股价下跌了3.66%，至16.57美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发